The Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) funding program from the National Institutes of Health (NIH) supports high-risk, high-impact, early discovery research on vaccine approaches to prevent the acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this program supports a Go/No-Go approach to funding high-risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2. Applications are open to researchers in the USA and worldwide. Applicants may apply for up to 350,000 USD/year for up to 4 years. Opportunity ID: PAR-23-169. Letters of intent are due July 2, 2023. Full applications are due August 2, 2023.